I. Legal/Regulatory authority and structures and procedures providing for post- and preapproval:
   A. Appropriate statutory mandate and jurisdiction.
   B. Ability to issue and update binding requirements on GMP’s and guidance documents.
   C. Authority to make inspections, review and copy documents, and to take samples and collect other evidence.
   D. Ability to enforce requirements and to remove products found in violation of such requirements from the market.
   E. Substantive current good manufacturing requirements.
   F. Accountability of the regulatory authority.
   G. Inventory of current products and manufacturers.
   H. System for maintaining or accessing inspection reports, samples and other analytical data, and other firm/product information relating to matters covered by subpart A of this part.

II. Mechanisms in place to assure appropriate professional standards and avoidance of conflicts of interest.

III. Administration of the regulatory authority:
   A. Standards of education/qualification and training.
   B. Effective quality assurance systems measures to ensure adequate job performance.
   C. Appropriate staffing and resources to enforce laws and regulations.

IV. Conduct of inspections:
   A. Adequate preinspection preparation, including appropriate expertise of investigator/team, review of firm/product and databases, and availability of appropriate inspection equipment.
   B. Adequate conduct of inspection, including statutory access to facilities, effective response to refusals, depth and competence of evaluation of operations, systems and documentation; collection of evidence; appropriate duration of inspection and completeness of written report of observations to firm management.
   C. Adequate postinspection activities, including completeness of inspectors’ report, inspection report review where appropriate, and conduct of followup inspections and other activities where appropriate, assurance of preservation and retrieval of records.

V. Execution of regulatory enforcement actions to achieve corrections, designed to prevent future violations, and to remove products found in violation of requirements from the market.

VI. Effective use of surveillance systems:
   A. Sampling and analysis.
   B. Recall monitoring.
   C. Product defect reporting system.
   D. Routine surveillance inspections.
   E. Verification of approved manufacturing process changes to marketing authorizations/approved applications.

VII. Additional specific criteria for preapproval inspections:
   A. Satisfactory demonstration through a jointly developed and administered training program and joint inspections to assess the regulatory authorities’ capabilities.
   B. Preinspection preparation includes the review of appropriate records, including site plans and drug master file or similar documentation to enable adequate inspections.
   C. Ability to verify chemistry, manufacturing, and control data supporting an application is authentic and complete.
   D. Ability to assess and evaluate research and development data as scientifically sound, especially transfer technology of pilot, scale up and full scale production batches.
   E. Ability to verify conformity of the onsite processes and procedures with those described in the application.
   F. Review and evaluate equipment installation, operational and performance qualification data, and evaluate test method validation.

APPENDIX E TO SUBPART A OF PART 26—
ELEMENTS TO BE CONSIDERED IN DEVELOPING A TWO-WAY ALERT SYSTEM

1. Documentation
   —Definition of a crisis/emergency and under what circumstances an alert is required
   —Standard Operating Procedures (SOP’s)
   —Mechanism of health hazards evaluation and classification
   —Language of communication and transmission of information

2. Crisis Management System
   —Crisis analysis and communication mechanisms
   —Establishment of contact points
   —Reporting mechanisms

3. Enforcement Procedures
   —Followup mechanisms
   —Corrective action procedures
4. Quality Assurance System
—Pharmacovigilance programme
—Surveillance/monitoring of implementation of corrective action

5. Contact Points
For the purpose of subpart A of this part, the contact points for the alert system will be:

A. For the European Community:

B. For the United States:


Subpart B—Specific Sector Provisions for Medical Devices

§ 26.31 Purpose.
(a) The purpose of this subpart is to specify the conditions under which a party will accept the results of quality system-related evaluations and inspections and premarket evaluations of the other party with regard to medical devices as conducted by listed conformity assessment bodies (CAB’s) and to provide for other related cooperative activities.
(b) This subpart is intended to evolve as programs and policies of the parties evolve. The parties will review this subpart periodically, in order to assess progress and identify potential enhancements to this subpart as Food and Drug Administration (FDA) and European Community (EC) policies evolve over time.

§ 26.32 Scope.
(a) The provisions of this subpart shall apply to the exchange and, where appropriate, endorsement of the following types of reports from conformity assessment bodies (CAB’s) assessed to be equivalent:
(1) Under the U.S. system, surveillance/postmarket and initial/preapproval inspection reports;
(2) Under the U.S. system, premarket (510(k)) product evaluation reports;
(3) Under the European Community (EC) system, quality system evaluation reports; and
(4) Under the EC system, EC type examination and verification reports.
(b) Appendix A of this subpart names the legislation, regulations, and related procedures under which:
(1) Products are regulated as medical devices by each party;
(2) CAB’s are designated and confirmed; and
(3) These reports are prepared.
(c) For purposes of this subpart, equivalence means that: CAB’s in the EC are capable of conducting product and quality systems evaluations against U.S. regulatory requirements in a manner equivalent to those conducted by FDA; and CAB’s in the United States are capable of conducting product and quality systems evaluations against EC regulatory requirements in a manner equivalent to those conducted by EC CAB’s.

§ 26.33 Product coverage.
(a) There are three components to this subpart each covering a discrete range of products:
(1) Quality System Evaluations. U.S.-type surveillance/postmarket and initial/preapproval inspection reports and European Community (EC)-type quality system evaluation reports will be exchanged with regard to all products regulated under both U.S. and EC law as medical devices.
(2) Product Evaluation. U.S.-type premarket (510(k)) product evaluation reports and EC-type-testing reports will be exchanged only with regard to those products classified under the U.S. system as Class I/Class II-Tier 2 medical devices which are listed in appendix B of this subpart.
(3) Postmarket Vigilance Reports. Postmarket vigilance reports will be exchanged with regard to all products regulated under both U.S. and EC law as medical devices.